A4978
Alendronate sodium trihydrate
≥97% (NMR), powder
Sinonimo/i:
4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid, monosodium, MK-217
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C4H12NaNO7P2 · 3 H2O
Numero CAS:
Peso molecolare:
325.12
Numero MDL:
Codice UNSPSC:
41106300
ID PubChem:
NACRES:
NA.77
Prodotti consigliati
Livello qualitativo
Saggio
≥97% (NMR)
Stato
powder
Colore
white
Solubilità
water, double-distilled: 10 mg/mL
Temperatura di conservazione
−20°C
Stringa SMILE
[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O
InChI
1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1
DCSBSVSZJRSITC-UHFFFAOYSA-M
Informazioni sul gene
human ... FDPS(2224)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Applicazioni
Alendronate sodium trihydrate has been used:
- for calcium phosphate nanoparticles (nCaP)/ bisphosphonate (BP) coating on titanium implants and analyze its osteogenic capacity
- in osteogenic differentiation of human bone marrow stromal cells (hBMSCs) isolated from aged osteoporosis patients- and healthy-person
- to treat osteoblast progenitor cells and osteoblasts and study their effect on osteoblast behaviors using conventional assays and simple digital image analysis
Azioni biochim/fisiol
Alendronate is a nitrogen-containing bisphosphonate that is known to hinder the mevalonate pathway and limit osteoclastic function and activity. Alendronate sodium trihydrate is a bone resorption inhibitor, farnesyl diphosphate synthase inhibitor, and CD45 protein tyrosine phosphatase inhibitor.
Alendronate sodium trihydrate is a bone resorption inhibitor; farnesyl diphosphate synthase inhibitor (IC50 = 460 nM); CD45 protein tyrosine phosphatase inhibitor.
Stoccaggio e stabilità
Following reconstitution, it is recommended to aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at -20°C.
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 4 Oral
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Dispositivi di protezione individuale
dust mask type N95 (US), Eyeshields, Gloves
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Robert Josse et al.
Current medical research and opinion, 29(3), 205-216 (2013-01-10)
According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
Mattias Ulmner et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
Shmuel Banai et al.
American heart journal, 165(2), 234-240 (2013-01-29)
Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose
Xuefeng Hu et al.
Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)
Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis
Wei-Yih Chiu et al.
The Journal of clinical endocrinology and metabolism, 98(4), E723-E726 (2013-03-09)
Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.